Phagocytosis and killing ability of *Candida albicans* by blood leucocytes of healthy term and preterm babies

M. XANTHOU, E. VALASSI-ADAM, E. KINTZONIDOU, and N. MATSANIOTIS

*From the Department of Paediatrics, University of Athens*

Various functions of newborn leucocytes have been the subject of much recent work in order to explain the notorious susceptibility of neonates to infection. Particular attention has been paid to the ability of leucocytes to phagocytize and subsequently kill pathogenic micro-organisms like *Esch. coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, etc. Both these functions were found to be deficient and more so in the preterm infants mainly because of opsonic deficiencies in their serum. Addition of adult serum would in most instances correct the phagocytosis and killing defects (Forman and Stiehm, 1969; Miyamoto, 1965a, b; Dossett, Williams, and Quie, 1969; Park, Holmes, and Good, 1970; McCracken and Eichenwald, 1971).

The high incidence of monilia infection in the newborn has stimulated us to test these leucocyte functions with *C. albicans*; moreover, candida has a particular immunological interest as candidiasis often accompanies either a fall in host resistance or immunological defects.

**Patients and methods**

The phagocytosis and candidacidal ability of leucocytes were studied in 24 term and 22 preterm babies. 14 adults 20 to 30 years of age were used as controls. Out of the 46 newborns, 4 term and 2 preterm babies were small-for-dates. 11 preterm babies had a gestational age <32 weeks, and 11 >32 weeks. The postnatal age ranged from 1 to 20 days with a mean of 6 days.

All babies were healthy at the time of the test apart from 11 term and 4 preterm babies who had jaundice but were otherwise doing very well. The aetiology of jaundice was Rh incompatibility in 3, G6PD deficiency in 3, ABO incompatibility in 1, and unknown origin in the remaining 8. Finally, all babies included in this study received prophylactic antibiotic therapy (penicillin and gentamicin for 7–10 days) because of prolonged rupture of membranes or because of poor means of transportation to our unit. The blood specimens were obtained either by venepuncture or from a free-flowing heel prick.

Phagocytosis and killing abilities were evaluated by the method described by Lehrer and Cline (1969) with minor modifications. Similar numbers of polymorphonuclear neutrophils and viable candidae in a mixture of Hanks’s...
Phagocytosis and killing ability of Candida albicans by blood leucocytes of babies

Salt solution and patient's serum were incubated for 30 minutes at 37 °C and the percentage of intracellular candidae was determined for estimation of phagocytosis. The determination of killing ability was based on differential staining of nonviable candidae which take methylene blue dye and acquire a deep blue colour being thus clearly distinguished from viable organisms which do not take the stain and remain white. The method was chosen as more reliable and simpler than the ones relying on the counting of colonies on cultures.

Lehrer and Cline (1969) used 10 ml of blood and suspended the cells in fetal calf serum and dextran. We had to minimize the amount of blood taken in newborn babies and worked with a maximum of 4 ml from which we managed to separate an adequate number of leucocytes using dextran only. However, the test with smaller numbers of leucocytes and consequently candidae was more time consuming.

Phagocytosis was expressed as the number of phagocytosed candidae per 100 organisms. Candidacidal ability was expressed (a) as the number of nonviable candidae per 100 phagocytosed organisms, (b) as the number of nonviable candidae per 100 organisms (crude phagocytosis). No distinction was made regarding the type of phagocytosing leucocytes whether polymorphonuclear neutrophils, eosinophils, or monocytes.

Finally C3 levels were measured by radial immunodiffusion using \( \beta_1C/\beta_2A \) antiserum and home-made immunoplates.

**Results**

Phagocytosis and candidacidal ability of leucocytes were very similar in jaundiced, small-for-dates, and healthy newborns. Therefore, all these babies were included in the same groups.

**Phagocytosis.** Adult leucocytes in their own serum had a mean phagocytosis value of 66·7%. Term and preterm babies' leucocytes in their own serum had a mean phagocytosis value of 57% and 56·9%, respectively. The values in adults ranged from 41% to 94%. An even larger range (23·6%–92·5%) was found in newborns (Fig. 1).

Although adult leucocytes tend to have a better ability to phagocytize *C. albicans*, no significant difference was found between their ability and that of term or preterm babies. In preterm babies no difference in phagocytosis was found between those of less than 32 weeks' gestation and those above it. The addition of adult serum did not affect to any appreciable degree the phagocytosis in term or preterm babies.

**Candidacidal ability.** The ability of adult leucocytes in their own serum to kill ingested *C. albicans* had a mean geometric value of 27·5%. The newborn leucocytes in their own serum had a much lower candidacidal ability, the mean geometric value for the term infants being 9·7%, and for the pretermers 9·5%. There was no difference in the candidacidal ability between term and preterm babies nor between preterm babies above and below 32 weeks of gestation. However, the difference in the candidacidal ability between adults and term babies as well as between adults and preterm babies was found to be highly significant (P <0·001 and P <0·01, respectively). The range of the killing ability of leucocytes was again wider in the newborns, some of whom had no candidacidal ability at all (Fig. 2). The addition of adult serum did not improve the candidacidal ability of the leucocytes in term or preterm babies.

Finally, regarding the crude candidacidal ability, the adults' leucocytes were found again to be significantly better when compared with that of the newborns.

**Complement.** C3 levels ranged from 22 mg/100 ml to 265 mg/100 ml with a mean value of 99·6 mg/100 ml in newborns. Though the C3
component of complement tended to increase with gestational age, no significant statistical differences were found between term and preterm babies. The concentration of C3 did not show any correlation with phagocytosis or killing ability of newborn leucocytes.

Finally, the postnatal age did not have any correlation with the above functions of leucocytes.

**Discussion**

We have found that the phagocytosis of *C. albicans* by adult leucocytes, though superior to that of the term or preterm newborns, did not differ significantly. The addition of adult serum had no effect on this function of the newborn's leucocytes.

These findings contrast with those of other investigators who, using various bacteria, found the ability of the leucocytes of newborn and particularly of preterm babies to phagocyte to be deficient and to improve considerably with the addition of adult serum (Forman and Stiehm, 1969; Miyamoto, 1965a, b; McCracken and Eichenwald, 1971). That serum opsonins are important for the phagocytosis of candida has been shown with mouse (Morelli and Rosenberg, 1971) and adult (Lehrer and Cline, 1969) leucocytes.

There is no doubt that the newborn's serum is deficient in opsonic activity (Dossett, 1972), and our findings regarding the C3 levels in the serum of the babies we examined confirm this finding.* However, Miller (1969) reported the newborn's serum opsonic deficiency to be apparent only when serum dilutions exceeded 10%.

Our findings regarding efficient phagocytosis of candida by the newborn's leucocytes in their own serum could be explained in that the term or preterm babies' serum in the 25% dilution, which we used, provides adequate opsonins for a normal phagocytosis.

The ability of newborn leucocytes to kill the ingested candidae was found to be significantly lower compared with that of adult leucocytes.

Although serum factors seem to enhance the killing ability of newborn leucocytes towards various micro-organisms (Dossett *et al.*, 1969; Forman and Stiehm, 1969; Park *et al.*, 1970; McCracken and Eichenwald, 1971) exposure of our newborn leucocytes to adult serum did not improve their killing capacity. That the killing ability of candida is not influenced by serum factors has been shown by Morelli and Rosenberg (1971) with mice leucocytes and Lehrer and Cline (1969) with adult leucocytes. Our findings strongly suggest that the killing defect of newborn leucocytes towards *C. albicans* should not be sought in serum factors but in the leucocyte itself.

Of further interest is our finding that the leucocytes of the preterm babies are as efficient against *C. albicans* as those of the term babies. That preterm babies can be sensitized and produce antibodies as well as term babies has already been shown (Uhr, Dancis, and Newmann, 1960).

Finally, it should be noted that all these experiments were *in vitro* and that *in vivo* the deficiency of the newborn's leucocytes to handle candida infection may be further enhanced by the immature cell-mediated immunity of the newborn (Dossett, 1972; Matsaniotis, Economou-Mavrou, and Tsenghi, 1967).

**REFERENCES**


*Values in newborns of the present series are equivalent to 50% of adult values in the Greek population.*
**Phagocytosis and killing ability of Candida albicans by blood leucocytes of babies** 75


Correspondence to Dr. M. Xanthou, Department of Paediatrics, ‘St. Sophie’s’ Children’s Hospital, Athens 608, Greece.
Phagocytosis and killing ability of Candida albicans by blood leucocytes of healthy term and preterm babies.

M Xanthou, E Valassi-Adam, E Kintsonidou and N Matsaniotis

Arch Dis Child 1975 50: 72-75
doi: 10.1136/adc.50.1.72

Updated information and services can be found at:
http://adc.bmj.com/content/50/1/72

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/